The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing to offer 340B prices to providers that use contract pharmacies. Six of the referrals from HRSA are more than a year and a half old.
“OIG does not comment publicly on potential or pending enforcement matters,” a spokesperson said. “However, in all matters, OIG carefully considers all facts and circumstances when determining whether to pursue civil monetary penalties.”
The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing to offer […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
